WO2018139047A1 - Fibres adsorbant l'urée, leur procédé de fabrication, filtre de purification du sang et appareil de purification du sang les utilisant - Google Patents

Fibres adsorbant l'urée, leur procédé de fabrication, filtre de purification du sang et appareil de purification du sang les utilisant Download PDF

Info

Publication number
WO2018139047A1
WO2018139047A1 PCT/JP2017/043084 JP2017043084W WO2018139047A1 WO 2018139047 A1 WO2018139047 A1 WO 2018139047A1 JP 2017043084 W JP2017043084 W JP 2017043084W WO 2018139047 A1 WO2018139047 A1 WO 2018139047A1
Authority
WO
WIPO (PCT)
Prior art keywords
urea
zeolite
blood purification
fiber
polymer
Prior art date
Application number
PCT/JP2017/043084
Other languages
English (en)
Japanese (ja)
Inventor
充宏 荏原
Original Assignee
国立研究開発法人物質・材料研究機構
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 国立研究開発法人物質・材料研究機構 filed Critical 国立研究開発法人物質・材料研究機構
Priority to JP2018564133A priority Critical patent/JPWO2018139047A1/ja
Publication of WO2018139047A1 publication Critical patent/WO2018139047A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
    • B01J20/10—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
    • B01J20/16—Alumino-silicates
    • B01J20/18—Synthetic zeolitic molecular sieves
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating

Definitions

  • the present invention relates to a urea-adsorbing fiber using a water-insoluble polymer and zeolite, a production method thereof, a blood purification filter using the same, and a blood purification device using the same.
  • Hemodialysis requires a large amount of water of 120L or more per patient and electricity that can operate the device. For this reason, hemodialysis requires complete water and electricity infrastructure. Furthermore, for dialysis patients, the number of visits related to hemodialysis (3 times a week) and treatment time (4 hours once) are very heavy. Inability to perform dialysis treatment occurs. Moreover, the same problem also occurs in an emergency when the lifeline is cut off.
  • Acute uremia can be treated quickly by quickly removing uremic toxins and excess water from the body.
  • conventional treatments for acute uremia have been based on diffusion and filtration, so that emergency treatment is difficult in an environment where infrastructure is not perfect.
  • the adsorption column used in the direct blood perfusion method or plasma adsorption can selectively remove the pathogenic substance and does not require a replacement solution or dialysate.
  • the adsorption column has a problem that the stimulation to blood is large and an anticoagulant cannot be avoided.
  • QOL quality of life
  • Patent Document 1 a blood purification membrane that has excellent blood compatibility and rapidly removes creatinine has been developed (see, for example, Patent Document 1).
  • the membrane for blood purification of Patent Document 1 is composed of a fiber and particles attached to the fiber, the fiber is composed of a polymer insoluble in water, the particle contains SiO 2 and Al 2 O 3 , and the particle contains uremic toxins. Is provided with a pore capable of taking in at least a part of it, rapidly adsorbing creatinine, and excellent in blood compatibility.
  • there are about 100 types of uremic toxins and it is desired to develop a material that efficiently removes specific uremic toxins in addition to creatinine.
  • An object of the present invention is to provide a urea-adsorbing fiber that efficiently adsorbs urea, a manufacturing method thereof, a blood purification filter using the same, and a blood purification device using the same.
  • the urea-adsorbing fiber containing a water-insoluble polymer and zeolite has a SiO 2 / Al 2 O 3 molar ratio of 15 to 50 in the zeolite, and the zeolite is incorporated into the polymer.
  • the molar ratio of SiO 2 / Al 2 O 3 in the zeolite may satisfy 35 or more and 45 or less.
  • the zeolite may be contained in a range of 3 wt% to 50 wt%.
  • the zeolite may be contained in a range of 3 wt% to 15 wt%.
  • the zeolite may be contained in a range of 5 wt% to 11 wt%.
  • the zeolite may have a particle size in the range of 10 nm to 10 ⁇ m.
  • the zeolite may be dispersed and incorporated in the polymer.
  • the polymer may be selected from the group consisting of ethylene-vinyl alcohol copolymer (EVOH), polyvinyl pyrrolidone (PVP), polyhydroxyethyl methacrylate (PHEMA) and polyvinyl alcohol (PVA).
  • EVOH ethylene-vinyl alcohol copolymer
  • PVP polyvinyl pyrrolidone
  • PHEMA polyhydroxyethyl methacrylate
  • PVA polyvinyl alcohol
  • the urea adsorption fiber may have a fiber diameter in a range of 100 nm to 1000 nm.
  • the method for producing the urea-adsorbing fiber according to the present invention includes a step of preparing a dispersion containing a polymer insoluble in water and a zeolite, and a step of spinning from the dispersion by an electrospinning method. Solve the above problems.
  • the blood purification filter according to the present invention contains the urea adsorption fiber, thereby solving the above-mentioned problems.
  • the blood purification apparatus according to the present invention includes the blood purification filter, thereby solving the above-described problems.
  • the urea-adsorbing fiber according to the present invention can efficiently adsorb urea among uremic toxins by using zeolite having a SiO 2 / Al 2 O 3 molar ratio of 15 to 50. Furthermore, according to the urea-adsorbing fiber of the present invention, since the zeolite is taken into the water-insoluble polymer, blood components such as platelets and leukocytes other than urea do not come into direct contact with the zeolite. As a result, it exhibits an anticoagulant action and an anti-inflammatory action.
  • Such a urea-adsorbing fiber is suitable for a blood purification filter that adsorbs and removes urea from uremic toxins in blood, and also a blood purification apparatus using the same.
  • blood purification devices equipped with blood purification filters using urea-adsorbing fibers do not require the supply of dialysate, so they can be made smaller and even wearable, and in environments where infrastructure and other facilities are not perfect. Can also be used.
  • the flowchart which shows the step which manufactures the urea adsorption fiber of this invention Schematic diagram showing spinning by electrospinning method
  • the schematic diagram which shows the blood purification system provided with the blood purification apparatus by this invention Schematic diagram showing an exemplary blood purification filter mounted on the blood purification apparatus of the present invention.
  • the figure which shows the result of urea adsorption property evaluation of the zeolite of Reference Examples 1-5 The figure which shows the time dependence of the urea adsorption amount of the film
  • the urea-adsorbing fiber according to the present invention contains a water-insoluble polymer and zeolite.
  • the molar ratio of SiO 2 / Al 2 O 3 satisfies 15 or more and 50 or less.
  • the present inventors have found that urea can be efficiently adsorbed among uremic toxins by using zeolite having a specific molar ratio.
  • the zeolite whose molar ratio is controlled in this way is incorporated (covered) in the polymer, blood components other than urea (platelets, leukocytes, etc.) do not come into direct contact with the zeolite. As a result, it exhibits an anticoagulant action and an anti-inflammatory action.
  • the molar ratio of SiO 2 / Al 2 O 3 preferably satisfies 35 or more and 45 or less. If zeolite satisfying such a molar ratio is used, urea can be reliably adsorbed.
  • the zeolite having the crystal form of ZSM-5 and / or mordenite has micropores and mesopores suitable for urea adsorption.
  • Zeolite is preferably contained in the range of 3 wt% to 50 wt% in all fibers. If the zeolite content is less than 3 wt%, urea may not be sufficiently adsorbed. When the content of zeolite exceeds 50 wt%, the amount of zeolite is too much and aggregates in the polymer, which may reduce the adsorption efficiency of urea.
  • Zeolite is preferably contained in the range of 3 wt% to 15 wt%. If the zeolite content is within this range, a urea adsorption fiber having high urea adsorption efficiency can be provided. More preferably, the zeolite is contained in a range of 5 wt% to 11 wt%. If the content of the zeolite is within this range, it is possible to provide a urea-adsorbing fiber in which the zeolite is efficiently dispersed in the polymer and exhibits extremely high urea adsorption efficiency.
  • the zeolite preferably has a particulate form having a particle size in the range of 10 nm to 10 ⁇ m. Any zeolite having a particle size in this range can be incorporated into the polymer. More preferably, the zeolite has a particle size in the range of 10 nm to 100 nm. Thereby, the zeolite can be uniformly dispersed and incorporated without agglomerating in the polymer, so that urea can be adsorbed efficiently.
  • the particle diameter is a volume-based median diameter (D50).
  • the zeolite may be a complex with a metal organic structure (MOF: Metal Organic Frameworks) as long as it has the above characteristics.
  • MOF Metal Organic Frameworks
  • it is designed so that it may have a pore which can take in urea. Thereby, the adsorption efficiency of urea can be further improved.
  • the polymer insoluble in water is a hydrophilic polymer insoluble in water and can be obtained by performing insolubilization treatment such as crosslinking.
  • the water insoluble polymer is selected from the group consisting of ethylene-vinyl alcohol copolymer (EVOH), polyvinyl pyrrolidone (PVP), polyhydroxyethyl methacrylate (PHEMA) and polyvinyl alcohol (PVA).
  • EVOH is preferable because it does not require insolubilization and has excellent biocompatibility.
  • the urea adsorption fiber of the present invention has a fiber diameter in the range of 100 nm to 1000 nm. If it has such a fiber diameter, a zeolite can be reliably taken in in a polymer. In addition, if a urea adsorbing fiber having such a fiber diameter is used, a mesh-like film or bulk body having a large number of fine pores can be produced when processed into a film or bulk body. Such a film or bulk body can quickly take in urea in the blood into the fiber, and thus can function as a blood purification filter.
  • FIG. 1 is a flowchart showing steps for producing the urea-adsorbing fiber of the present invention.
  • Step S110 A dispersion containing a water-insoluble polymer and zeolite is prepared. Since the water-insoluble polymer and zeolite are as described above, description thereof is omitted.
  • the solvent is not particularly limited as long as it dissolves a water-insoluble polymer and disperses the zeolite.
  • hexafluoroisopropanol a mixed solvent of isopropanol and water, or the like can be used.
  • the mixing ratio of the solvent and water is, for example, 10:90 to 90:10 (v / v).
  • Hexafluoroisopropanol is preferable because it can be used at room temperature.
  • the concentration of zeolite in the dispersion preferably satisfies the range of 0.1 wt% to 10 wt%. Within this range, the zeolite can be uniformly dispersed in the dispersion. It is preferable to perform ultrasonic treatment to uniformly disperse the zeolite.
  • the polymer concentration in the dispersion preferably satisfies the range of 1 wt% to 15 wt%. Within this range, spinning by an electrospinning (electrospinning) method described later is possible. More preferably, the polymer concentration satisfies the range of 5 wt% or more and 8 wt% or less. Thereby, the urea adsorption fiber which has the above-mentioned fiber diameter in the range of 100 nm or more and 1000 nm or less is obtained.
  • such a dispersion may be prepared by mixing a polymer solution in which a polymer is dissolved in the solvent and a zeolite dispersion in which zeolite is dispersed in the solvent. If the mixing ratio of the zeolite to the polymer (wt%) is 5 wt% or more and 55 wt% or less, the zeolite content (wt%) in the fiber finally obtained is 3 wt% or more and 50 wt% or less. can do.
  • Step S120 Spinning from the dispersion prepared in step S110 by electrospinning.
  • FIG. 2 is a schematic diagram showing a state of spinning by an electrospinning method.
  • an electric field is applied between the spinning port 61A of the container 61 filled with the dispersion 63 and the collector 62 by a high-voltage power supply device.
  • the dispersion liquid 63 is jetted from the spinneret 61 ⁇ / b> A toward the collector 62.
  • the solvent is volatilized from the jetted dispersion 63, and the urea adsorption fiber 99 is manufactured.
  • a film or a bulk body in which urea adsorption fibers are aggregated and accumulated can be produced. Or it is good also as a bulk body by filtering the obtained urea adsorption fiber.
  • Such a laminate or bulk body in which films using urea adsorption fibers are laminated uses urea adsorption fibers that effectively adsorb urea among uremic toxins in blood as described above. It functions as a blood purification filter that can purify blood.
  • a urea-adsorbing filter that adsorbs urea more efficiently may be obtained by rolling a membrane containing urea-adsorbing fibers and processing it into a hollow fiber shape or using a cylindrical member as a collector during spinning.
  • urea-adsorbing fiber of the present invention if a laminate or bulk body composed of a film using other uremic toxins, for example, the creatinine-adsorbing fiber described in Patent Document 1, is manufactured, in addition to urea It goes without saying that a filter that also adsorbs creatinine can be provided. Such a combination can be appropriately adjusted according to the symptoms of the patient.
  • Embodiment 2 a blood purification apparatus will be described in detail as an application using the urea adsorption fiber of the present invention.
  • FIG. 3 is a schematic diagram showing a dialysis system equipped with a blood purification apparatus according to the present invention.
  • a blood purification system 300 includes a blood purification device 320 including a blood purification filter 310. Since the blood purification filter 310 uses the urea adsorption fiber described in the first embodiment, the description thereof is omitted.
  • a tube 330 is connected to an artery, and a tube 340 is connected to a vein.
  • Blood containing uremic toxins is supplied from the body to the blood purification device 320 via the tube 330, and the blood from which uremic toxins have been removed is returned to the body via the tube 340.
  • a blood pump 350 is connected to the tube 330, and blood is supplied to the blood purification filter 310 of the blood purification apparatus 300.
  • an arterial pressure measurement device, an anticoagulant addition device, and the like may be connected to the tube 330 in addition to this.
  • an ultrasonic air detector and a venous pressure measuring device may be connected to the tube 340.
  • the blood purification filter 310 contains urea adsorption fibers, urea as a uremic toxin is efficiently and selectively adsorbed by the zeolite in the fibers, and the red blood cells pass through the gap between the fibers without being adsorbed.
  • small molecules are removed based on the principle of “sieving”, so that some of the molecules are left behind.
  • “sieving” can be performed against urea. Since positive “adsorption” is performed in addition to the principle, the removal efficiency can be significantly improved.
  • zeolite is taken into a water-insoluble polymer and does not come into direct contact with blood, platelets are not activated and blood coagulation is suppressed.
  • leukocytes do not attack the zeolite, inflammation is suppressed. Therefore, an anticoagulant or an anti-inflammatory agent can be dispensed with. In this way, blood purification apparatus 320 can efficiently discharge blood from which urea, which is uremic toxin, has been removed from blood.
  • the blood purification system 300 can eliminate the need for a dialysate supply / discharge device, and the mounted blood purification filter 310 is efficient against urea as described above. In order to enable easy adsorption, it becomes more compact than before. Since it is only necessary to replace the blood purification filter 310 at the time of use, the blood purification apparatus 320 can be worn, and not only the dialysis patient is freed from troublesome machines but also infrastructure such as electricity and water is not maintained. Dialysis (ie, blood purification) is possible even under difficult circumstances.
  • FIG. 4 is a schematic view showing an exemplary blood purification filter mounted on the blood purification apparatus of the present invention.
  • the form of the blood purification filter 310 is not particularly limited.
  • a film containing urea-adsorbing fibers may be laminated, or FIG. As shown in B), it may be a bulk body in which urea adsorption fibers are accumulated, or may be a hollow fiber of a membrane containing urea adsorption fibers, as shown in FIG. 4C.
  • the blood purification filter 310 can be provided at low cost.
  • the surface area of the filter is increased, so that urea in the blood is more efficiently removed and the dialysis time can be shortened.
  • the bulk body has a hole penetrating in the direction in which blood passes, or the hollow fiber of FIG.
  • the dialysate supply device and the dialyzer can be connected to supply / discharge dialysate and water via a heater, a pump, or the like.
  • Reference Examples 1 to 5 the urea adsorption characteristics of zeolites having various molar ratios of SiO 2 / Al 2 O 3 were evaluated.
  • zeolite manufactured by Tosoh Corporation
  • protein metabolite urea manufactured by Wako Pure Chemical Industries, Ltd.
  • Urea was dissolved in water to prepare a 191 ⁇ M urea aqueous solution.
  • Table 1 shows the model number, molar ratio, particle size, and crystal form of the zeolite used in Reference Examples 1 to 5. Please refer to the website of Tosoh Corporation for the model number.
  • Each zeolite was immersed in 5 mL of an aqueous urea solution for 5 hours, and the remaining solution after removing the zeolite was used as an evaluation solution.
  • a change in light absorption intensity at a peak wavelength of 233 nm was measured by a visible ultraviolet (UV-VIS) spectrometer, and urea adsorption was evaluated. The results are shown in FIG.
  • FIG. 5 is a diagram showing the results of evaluating the urea adsorptivity of the zeolites of Reference Examples 1 to 5.
  • urea was effectively adsorbed in the zeolites of Reference Example 2 and Reference Example 3, and among them, the zeolite of Reference Example 3 showed excellent adsorption of urea.
  • the molar ratio of SiO 2 / Al 2 O 3 in the zeolite satisfies 15 or more and 50 or less, particularly preferably SiO 2 in the zeolite. It was shown that the molar ratio of / Al 2 O 3 satisfies 35 or more and 45 or less. It has also been found that such zeolites have model night and / or ZSM-5 crystal forms.
  • Example 6 the zeolite of Reference Example 3 (model number HSZ-540HOA manufactured by Tosoh Corporation) that showed the most excellent urea adsorption performance in Reference Examples 1 to 5, and an ethylene-vinyl alcohol copolymer as a water-insoluble polymer. (EVOH, manufactured by Kuraray Co., Ltd., EVAL (registered trademark) E105B) was produced, and its urea adsorptivity was evaluated.
  • EVOH manufactured by Kuraray Co., Ltd., EVAL (registered trademark) E105B
  • a dispersion containing the polymer and zeolite was prepared (step S110 in FIG. 1).
  • the polymer and zeolite were dissolved in hexafluoroisopropanol as a dispersion.
  • the polymer concentration was 7 wt%
  • the zeolite concentration was 0.7 wt%.
  • a dispersion in which zeolite was uniformly dispersed was obtained by ultrasonic mixing. In the dispersion, the blending ratio of zeolite to polymer was 9 wt%, and the content of zeolite relative to the entire fiber was 8 wt%.
  • the electrospinning conditions were a voltage of 25 kV and an ejection speed of 1 mL / h.
  • a film made of fiber was produced.
  • membrane which consists of obtained fiber was observed with the scanning electron microscope, presence of the fiber which has a fiber diameter which satisfy
  • the urea adsorption characteristics of the membrane were evaluated using the urea aqueous solution used in Reference Examples 1 to 5.
  • the membrane was immersed in 5 mL of an aqueous urea solution for 24 hours, and the solution remaining after removing the membrane was used as the evaluation solution.
  • a change in light absorption intensity at a peak wavelength of 233 nm was measured by a visible ultraviolet (UV-VIS) spectrometer, and the urea adsorptivity was evaluated. The results are shown in FIGS.
  • Example 7 In Example 7, the concentration of zeolite in the dispersion was 3 wt%, the blending ratio of zeolite to polymer was 30 wt%, and the content of zeolite with respect to the entire fiber was 27 wt%, as in Example 6. Thus, a fiber was produced and its urea adsorption property was evaluated. The results are shown in FIGS.
  • Example 8 In Example 8, the concentration of zeolite in the dispersion was 5.7 wt%, the blending ratio of zeolite to polymer was 45 wt%, and the content of zeolite with respect to the entire fiber was 38 wt%. In the same manner as above, fibers were produced and their urea adsorptivity was evaluated. The results are shown in FIGS.
  • FIG. 6 is a graph showing the time dependence of the urea adsorption amount of the membrane made of the fiber of Example 6.
  • the adsorption amount of the membrane made of the fiber of Example 6 increased immediately after the start of the urea adsorption experiment and reached a plateau 3 hours after the start of the experiment. From such a tendency, it is suggested that the fiber is in a state in which the zeolite is incorporated into the polymer, and urea enters the fiber and is adsorbed on the zeolite.
  • FIG. 7 is a diagram showing the amount of urea adsorbed on 1 g of the fiber made of the fibers of Examples 6 to 8.
  • FIG. 7 shows the results of immersion for 4 hours and 12 hours.
  • the urea adsorption amount of a membrane made of a single polymer fiber not containing zeolite is shown as the zeolite content of 0 wt%.
  • FIG. 7 shows that the adsorption amount of urea increases as the zeolite content in the fiber increases. It was also confirmed that when no zeolite was contained, urea was not adsorbed. It was found that there was no substantial difference in the amount of urea adsorbed after immersion for 4 hours and 12 hours, and urea was efficiently adsorbed in a short time.
  • FIG. 8 is a diagram showing the amount of urea adsorbed on 1 g of zeolite in the membranes made of the fibers of Examples 6 to 8.
  • FIG. 8 shows the results of immersion for 4 hours and 12 hours.
  • the urea adsorption amount per gram of zeolite carried out in Reference Example 3 is shown as the zeolite content of 100 wt%.
  • the zeolite content is 3 wt% or more and 15 wt% or less, more surely 5 wt% or more and 11 wt% or less, the zeolite is incorporated in a dispersed state in the polymer. It is suggested that it can be improved. It was found that there was no substantial difference in the adsorption efficiency of urea after immersion for 4 hours and 12 hours, and urea was efficiently adsorbed in a short time.
  • FIGS. 6 to 8 it is shown that a fiber in which a zeolite having a SiO 2 / Al 2 O 3 molar ratio of 15 to 50 is incorporated into a polymer functions as a urea-adsorbing fiber. If this is processed into a membrane or the like, it is suggested that a blood purification filter for removing uremic toxins (especially urea) in blood and a blood purification apparatus using the same can be realized.
  • the urea adsorption fiber according to the present invention efficiently adsorbs urea among uremic toxins by using zeolite that satisfies a predetermined molar ratio. Since the blood purification filter containing such a fiber efficiently adsorbs and removes urea from uremic toxins in blood, a blood purification apparatus using the same can be provided.
  • a blood purification device equipped with a blood purification filter containing urea-adsorbing fibers does not require the supply of dialysate, so it can be downsized and even wearable, in the event of an emergency when the lifeline is severed, and It can also be used in environments where infrastructure and other facilities are not perfect.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • External Artificial Organs (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)

Abstract

La présente invention concerne des fibres adsorbant l'urée qui adsorbent efficacement l'urée, un procédé de fabrication de celles-ci, un filtre de purification du sang et un appareil de purification du sang les utilisant. Les fibres adsorbant l'urée selon un mode de réalisation de la présente invention contiennent un polymère non hydrosoluble et une zéolite, le rapport molaire SiO2/Al2O3 dans la zéolite variant de 20 à 50, et la zéolite étant incorporée dans le polymère.
PCT/JP2017/043084 2017-01-30 2017-11-30 Fibres adsorbant l'urée, leur procédé de fabrication, filtre de purification du sang et appareil de purification du sang les utilisant WO2018139047A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018564133A JPWO2018139047A1 (ja) 2017-01-30 2017-11-30 尿素吸着ファイバー、その製造方法、それを用いた血液浄化用フィルターおよびそれを用いた血液浄化装置

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017-014000 2017-01-30
JP2017014000 2017-01-30

Publications (1)

Publication Number Publication Date
WO2018139047A1 true WO2018139047A1 (fr) 2018-08-02

Family

ID=62979230

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/043084 WO2018139047A1 (fr) 2017-01-30 2017-11-30 Fibres adsorbant l'urée, leur procédé de fabrication, filtre de purification du sang et appareil de purification du sang les utilisant

Country Status (2)

Country Link
JP (1) JPWO2018139047A1 (fr)
WO (1) WO2018139047A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020152254A1 (fr) * 2019-01-24 2020-07-30 Previpharma Consulting Gmbh Réduction d'ions dans un fluide corporel par une zéolite
CN117696017A (zh) * 2024-02-05 2024-03-15 四川大学华西医院 一种血液净化吸附改性材料及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011526813A (ja) * 2008-07-01 2011-10-20 バクスター・インターナショナル・インコーポレイテッド 透析デバイスのためのナノクレイ吸着剤
WO2015029936A1 (fr) * 2013-08-26 2015-03-05 独立行政法人物質・材料研究機構 Membrane de purification de sang, procédé pour fabriquer une membrane de purification de sang, et dispositif de dialyse

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011526813A (ja) * 2008-07-01 2011-10-20 バクスター・インターナショナル・インコーポレイテッド 透析デバイスのためのナノクレイ吸着剤
WO2015029936A1 (fr) * 2013-08-26 2015-03-05 独立行政法人物質・材料研究機構 Membrane de purification de sang, procédé pour fabriquer une membrane de purification de sang, et dispositif de dialyse

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020152254A1 (fr) * 2019-01-24 2020-07-30 Previpharma Consulting Gmbh Réduction d'ions dans un fluide corporel par une zéolite
CN117696017A (zh) * 2024-02-05 2024-03-15 四川大学华西医院 一种血液净化吸附改性材料及其制备方法
CN117696017B (zh) * 2024-02-05 2024-05-07 四川大学华西医院 一种血液净化吸附改性材料及其制备方法

Also Published As

Publication number Publication date
JPWO2018139047A1 (ja) 2019-11-07

Similar Documents

Publication Publication Date Title
JP4211168B2 (ja) 透析器の製造方法および滅菌法
JP2016501576A (ja) 肝臓補助システム
WO2010074136A1 (fr) Membrane à fibre creuse poreuse et membrane à fibre creuse poreuse pour traiter un liquide contenant des protéines
FR2902670A1 (fr) Utilisation d'une suspension pour traiter un support a usage medical, support a usage medical, echangeur et dispositif d'adsorption comprenant le support
JP6252923B2 (ja) クレアチニン吸着ファイバー及びクレアチニン吸着ファイバーの製造方法
WO2009040123A1 (fr) Membranes hydrophiles comportant un tensioactif non ionique
WO2002034374A1 (fr) Membrane hydrophylisee et procede d'hydrophylisation
WO2018139047A1 (fr) Fibres adsorbant l'urée, leur procédé de fabrication, filtre de purification du sang et appareil de purification du sang les utilisant
WO2013129384A1 (fr) Colonne d'adsorption
EP3826765B1 (fr) Compositions pour utilisation dans l'élimination simultanée d'endotoxines et de solutés urémiques pendant le traitement de patients
EP4061519A1 (fr) Membranes poreuses comprenant des particules sorbantes pour capture améliorée d'urée
WO2020151228A1 (fr) Procédé de préparation d'une membrane à fibres creuses antibactérienne pour la purification du sang
JP4103037B2 (ja) 透析液清浄化用中空糸膜およびその製造方法
JP4569315B2 (ja) 改質中空糸膜
JP3424810B2 (ja) 高性能血液浄化膜
Davenport The changing face of dialyzer membranes and dialyzers
JP4381058B2 (ja) 血液適合性に優れた中空糸型血液浄化器
JP5177062B2 (ja) 分離膜デバイスおよびその製造方法
JP4148310B2 (ja) 白血球選択除去フィルター
US20190329188A1 (en) Membrane for the adsorption of bacteria
JP2016140616A (ja) 中空糸膜型血液浄化器およびその製造方法
JP2020093086A (ja) 分離膜デバイスおよびその製造方法
JP2020093249A (ja) 分離膜デバイスおよびその製造方法
JP2010017712A (ja) 中空糸膜および中空糸膜モジュール
JPS60172388A (ja) 水性液体の浄化方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17893765

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2018564133

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17893765

Country of ref document: EP

Kind code of ref document: A1